Similarly, an LPAR1 inhibitor, AM095, inhibits the expression of proinflammatory cytokines and fibrotic factors in the kidney, reduces glomerular matrix expansion, and improves kidney function in a streptozotocin-induced type 1 diabetic model [38]. The gene discussed is LPAR1; the disease is type 1 diabetes mellitus.